Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Analysis of Efficiency and Tolerance of Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis Occuring During First-line BRAFinh/MEKinh Therapy.

Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1 agent to TT may be proposed as a second line strategy. This observational survey aims at investigating the benefit/risk ratio of this triple combination in a small cohort of patients.

Inclusion criteria:

• Metastatic melanoma BRAF mutated
• Initially treated by a doubled targeted therapy anti BRAF/anti MEK
• With an intra cerebral progression of the tumor
• Whom we add an check point inhibitor anti PD1, combined with the double targeted therapy
• between 01/2019 et 01/2022

Exclusion criteria:

- Other condition